Keros is a Lexington, Massachusetts biopharmaceutical company developing protein therapies for neuromuscular and blood disorders. KROS reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 4 | Wells Fargo | Maintained | Buy | |
| Aug 4 | Leerink Partners | Maintained | Buy |
Seasonality
How KROS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in KROS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KROS is in one of them and how their past KROS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KROS in an article yet. Here's the latest on the wider market.
About Keros Therapeutics
Keros is a biopharmaceutical company in Lexington, Massachusetts, developing protein therapies for disorders linked to faulty signaling in the TGF-beta protein family, which helps control the growth and repair of muscle, bone, heart and blood tissue. Its lead candidate, rinvatercept, is in development for neuromuscular diseases such as Duchenne muscular dystrophy and ALS. Its most advanced candidate, elritercept, targets low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. The company's candidates are still in clinical development.
- Headquarters
- Lexington, MA